Abstract submission
is now open for the next EACPT Congress, to be held in Geneva 28-31 August
2013. The congress includes symposia, keynote lectures and peer-reviewed oral
and poster communications.
Symposium
on Personalizing Cancer Therapy
Inter-individual differences in patient responses to cancer therapies
are consistently observed. Personalizing cancer therapy refers to individualized
cancer patient management driven by host and tumor characteristics. Both organ
dysfonction and genetic alterations in drug disposition and targets may result
in suboptimal treatment or excessive toxicity. Therefore, personalized cancer
therapy ultimately aims at selecting the right drug and dose for the right
patient. The genetic characteristics of a tumor may also guide treatment and
molecular targeted therapies have indeed been a major breakthrough in oncology.
In this session, co-organized by the American Society of Clinical
Pharmacology and Therapeutics (ASCPT), three world-renowned experts will
examine the latest developments in tailoring cancer therapies, with a focus on
individualizing therapies in special populations, hematological malignancies
and breast cancer.
2013 EACPT Congress
Over 900 participants are expected to attend including
health professionals, scientists, policy makers, biotechnology and
pharmaceutical professionals, and others with an interest
in basic and clinical pharmacology, pharmacotherapy,
drug discovery and development, regulatory affairs and related
areas.
EACPT Geneva 2013 Congress website
www.eacpt2013.org
No comments:
Post a Comment